Therapies for macular edema associated with central retinal vein occlusion: A report by the American Academy of Ophthalmology

Ophthalmology

Volumn 122, Issue 4, 2015, Pages 769-778

  Yeh, Steven ^a   Kim, Stephen J ^b   Ho, Allen C ^c   Schoenberger, Scott D ^d   Bakri, Sophie J ^e   Ehlers, Justis P ^f   Thorne, Jennifer E ^g   Emptage, Nicholas ^h  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WILLS EYE HOSPITAL   (United States)

^d Retina Physicians and Surgeons Inc ^*  (United States)

^e MAYO CLINIC   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h MAE American Academy of Ophthalmology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; ANGIOGENESIS INHIBITOR; APTAMER; GLUCOCORTICOID; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ARTICLE; CATARACT; CENTRAL RETINA VEIN OCCLUSION; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; GLAUCOMA; HUMAN; LASER COAGULATION; MACULAR EDEMA; MONOTHERAPY; PRIORITY JOURNAL; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BIOMEDICAL TECHNOLOGY ASSESSMENT; DRUG COMBINATION; FACTUAL DATABASE; INTRAVITREAL DRUG ADMINISTRATION; OPHTHALMOLOGY; ORGANIZATION; ORGANIZATION AND MANAGEMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RETINAL VEIN OCCLUSION; TREATMENT OUTCOME; VISUAL ACUITY;

ACADEMIES AND INSTITUTES; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; OPHTHALMOLOGY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL VEIN OCCLUSION; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84925350584     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.10.013     Document Type: Article

References (47)

1. S. Rogers, R.L. McIntosh, and N. Cheung The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia Ophthalmology 117 2010 313 319
2. A.C. Fong, and H. Schatz Central retinal vein occlusion in young adults Surv Ophthalmol 37 1993 393 417
3. M.J. Koss, M. Pfister, and F. Rothweiler Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion Acta Ophthalmol 90 2012 e98 e103
4. L.P. Aiello, R.L. Avery, and P.G. Arrigg Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N Engl J Med 331 1994 1480 1487
5. S.R. Boyd, I. Zachary, and U. Chakravarthy Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion Arch Ophthalmol 120 2002 1644 1650
6. F.A. Gutman, and H. Zegarra Macular edema secondary to occlusion of the retinal veins Surv Ophthalmol 28 suppl 1984 462 470
7. M.L. Klein, and D. Finkelstein Macular grid photocoagulation for macular edema in central retinal vein occlusion Arch Ophthalmol 107 1989 1297 1302
8. Central Vein Occlusion Study Group Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: the Central Vein Occlusion Study Group M report Ophthalmology 102 1995 1425 1433
9. S.P. Park, and J.K. Ahn Changes of aqueous vascular endothelial growth factor and interleukin-6 after intravitreal triamcinolone for branch retinal vein occlusion Clin Experiment Ophthalmol 36 2008 831 835
10. J.H. Lee, M.D. Canny, and A. De Erkenez A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165 Proc Natl Acad Sci U S A 102 2005 18902 18907
11. J.J. Wroblewski, J.A. Wells 3rd, and A.P. Adamis Pegaptanib sodium for macular edema secondary to central retinal vein occlusion Arch Ophthalmol 127 2009 374 380
12. N. Ferrara, L. Damico, and N. Shams Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 2006 859 870
13. N. Ferrara, K.J. Hillan, H.P. Gerber, and W. Novotny Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 2004 391 400
14. J. Holash, S. Davis, and N. Papadopoulos VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci U S A 99 2002 11393 11398
15. M. Raszewska-Steglinska, P. Gozdek, and S. Cisiecki Pars plana vitrectomy with ILM peeling for macular edema secondary to retinal vein occlusion Eur J Ophthalmol 19 2009 1055 1062
16. E.M. Opremcak, A.J. Rehmar, and C.D. Ridenour Radial optic neurotomy with adjunctive intraocular triamcinolone for central retinal vein occlusion: 63 consecutive cases Retina 26 2006 306 313
17. E.M. Opremcak, A.J. Rehmar, C.D. Ridenour, and D.E. Kurz Radial optic neurotomy for central retinal vein occlusion: 117 consecutive cases Retina 26 2006 297 305
18. I.L. McAllister, M.E. Gillies, and L.A. Smithies The Central Retinal Vein Bypass Study: a trial of laser-induced chorioretinal venous anastomosis for central retinal vein occlusion Ophthalmology 117 2010 954 965
19. Central Vein Occlusion Study Group. Central vein occlusion study of photocoagulation therapy: baseline findings Online J Curr Clin Trials 1993 Doc No 95
20. M.S. Ip, I.U. Scott, and P.C. VanVeldhuisen A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5 Arch Ophthalmol 127 2009 1101 1114
21. J.A. Haller, F. Bandello, and R. Belfort Jr. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion Ophthalmology 117 2010 1134 1146
22. J.A. Haller, F. Bandello, and R. Belfort Jr. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results Ophthalmology 118 2011 2453 2460
23. D.M. Brown, P.A. Campochiaro, and R.P. Singh Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study Ophthalmology 117 2010 1124 1133
24. P.A. Campochiaro, D.M. Brown, and C.C. Awh Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study Ophthalmology 118 2011 2041 2049
25. J.S. Heier, P.A. Campochiaro, and L. Yau Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial Ophthalmology 119 2012 802 809
26. L.C. Zacharias, T. Lin, and R. Migon Assessment of the differences in pharmacokinetics and pharmacodynamics between four distinct formulations of triamcinolone acetonide Retina 33 2013 522 531
27. D. Boyer, J. Heier, and D.M. Brown Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study Ophthalmology 119 2012 1024 1032
28. D.M. Brown, J.S. Heier, and W.L. Clark Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study Am J Ophthalmol 155 2013 429 437
29. F.G. Holz, J. Roider, and Y. Ogura VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study Br J Ophthalmol 97 2013 278 284
30. D.L. Epstein, P.V. Algvere, and G. von Wendt Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study Ophthalmology 119 2012 1184 1189
31. D.L. Epstein, P.V. Algvere, and G. von Wendt Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study Ophthalmology 119 2012 2587 2591
32. H. Zhang, Z.L. Liu, P. Sun, and F. Gu Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial J Ocul Pharmacol Ther 27 2011 615 621
33. K. Kriechbaum, S. Michels, and F. Prager Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study Br J Ophthalmol 92 2008 518 522
34. F. Prager, S. Michels, and K. Kriechbaum Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial Br J Ophthalmol 93 2009 452 456
35. X. Ding, J. Li, and X. Hu Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion Retina 31 2011 838 845
36. W.J. Mayer, M. Remy, and A. Wolf Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema Ophthalmologica 228 2012 110 116
37. T. Aggermann, S. Brunner, I. Krebs ROVO Study Group A prospective, randomised, multicenter trial for surgical treatment of central retinal vein occlusion: results of the Radial Optic Neurotomy for Central Vein Occlusion (ROVO) Study Group Graefes Arch Clin Exp Ophthalmol 251 2013 1065 1072
38. P. Fortunato, L. Pollazzi, and M. Baroni Venous retinal flow reperfusion mechanisms following radial optic neurotomy with adjunctive intraocular triamcinolone in central retinal vein occlusion Graefes Arch Clin Exp Ophthalmol 248 2010 167 173
39. J.P. Ehlers, and S. Fekrat Retinal vein occlusion: beyond the acute event Surv Ophthalmol 56 2011 281 299
40. F.C. DeCroos, R.K. Shuler Jr., S. Stinnett, and S. Fekrat Pars plana vitrectomy, internal limiting membrane peeling, and panretinal endophotocoagulation for macular edema secondary to central retinal vein occlusion Am J Ophthalmol 147 2009 627 633
41. D.F. Martin, M.G. Maguire, and S.L. Fine Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
42. U. Chakravarthy, S.P. Harding, and C.A. Rogers Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 2012 1399 1411
43. S. Fekrat, A.M. Shea, and B.G. Hammill Resource use and costs of branch and central retinal vein occlusion in the elderly Curr Med Res Opin 26 2010 223 230
44. W.E. Smiddy Economic considerations of macular edema therapies Ophthalmology 118 2011 1827 1833
45. V.A. Deramo, T.A. Cox, and A.B. Syed Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire Arch Ophthalmol 121 2003 1297 1302
46. M.A. Chang, H.F. Fine, and E. Bass Patients' preferences in choosing therapy for retinal vein occlusions Retina 27 2007 789 797
47. R. Varma, N.M. Bressler, and I. Suner Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials Ophthalmology 119 2012 2108 2118